224 related articles for article (PubMed ID: 16164269)
1. [Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Kohjimoto Y; Iba A; Shintani Y; Uekado Y; Shinka T
Hinyokika Kiyo; 2005 Aug; 51(8):533-8. PubMed ID: 16164269
[TBL] [Abstract][Full Text] [Related]
2. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Skinner EC; Goldman B; Sakr WA; Petrylak DP; Lenz HJ; Lee CT; Wilson SS; Benson M; Lerner SP; Tangen CM; Thompson IM
J Urol; 2013 Oct; 190(4):1200-4. PubMed ID: 23597452
[TBL] [Abstract][Full Text] [Related]
3. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette-Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study.
Choi J; Kim KH; Kim HS; Yoon HS; Kim JH; Kim JW; Lee YS; Choi SY; Chang IH; Ko YH; Song W; Jeong BC; Nam JK
Investig Clin Urol; 2024 May; 65(3):248-255. PubMed ID: 38714515
[TBL] [Abstract][Full Text] [Related]
5. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
[TBL] [Abstract][Full Text] [Related]
6. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Haas CR; McKiernan JM
Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
9. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
10. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
[TBL] [Abstract][Full Text] [Related]
11. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
12. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Steinberg RL; Packiam VT; Thomas LJ; Brooks N; Vitale A; Mott SL; Crump T; Wang J; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
Dalbagni G; Russo P; Bochner B; Ben-Porat L; Sheinfeld J; Sogani P; Donat MS; Herr HW; Bajorin D
J Clin Oncol; 2006 Jun; 24(18):2729-34. PubMed ID: 16782913
[TBL] [Abstract][Full Text] [Related]
15. Combination Intravesical Therapy.
Brooks NA; O'Donnell MA
Urol Clin North Am; 2020 Feb; 47(1):83-91. PubMed ID: 31757303
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of intravesical bacillus Calmette-Guérin therapy with maintenance for urinary bladder carcinoma in situ: About 47 cases.
Sallami S; Khouni H; Ben Atta M; Abou El Makarim S; Zouari MB; Ben Rhouma S
Tunis Med; 2016 Dec; 94(12):844. PubMed ID: 28994883
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
Bassi P; De Marco V; Tavolini IM; Longo F; Pinto F; Zucchetti M; Crucitta E; Marini L; Dal Moro F
Urol Int; 2005; 75(4):309-13. PubMed ID: 16327296
[TBL] [Abstract][Full Text] [Related]
18. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
19. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]